Expression of D2 receptor in clinically nonfunctioning pituitary adenomas and its correlation with cabergoline treatment

• Grant number: 14/16327-1
• Support Opportunities: Regular Research Grants
• Duration: March 01, 2015 - May 31, 2017
• Field of knowledge: Biological Sciences - Genetics - Human and Medical Genetics
• Principal Investigator: Ericka Barbosa Trarbach
• Grantee: Ericka Barbosa Trarbach
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Malebranche Berardo Carneiro da Cunha Neto

Abstract

Clinically nonfunctioning pituitary adenomas (ACNF) represent about 30% of pituitary tumors. Are diagnosed early as incidentalomas sellar or later, when they reach sufficient size to cause compressive symptoms neuroftalmológicos and / or hypopituitarism. Macroadenomas (> 1 cm), treatment of choice for most patients is surgical resection. Although surgery can improve the visual change and eventually restore pituitary function in a large number of cases, due to the large tumor volume and growth potential, the result is not satisfactory, requiring adjuvant treatment. There are still patients who refuse surgery and other clinics in poor condition for the operation, in which medical treatment may be the first therapeutic option. The use of dopamine agonists in cases of persistent tumor has been reported, although there is one well established design so that not know the effectiveness of this treatment if tumor rest. In this project, we aimed to evaluate the therapeutic response to dopamine agonist (cabergoline) in patients with tumor remains after surgery and its correlation with the expression of dopamine receptors. Aim to demonstrate that clinical treatment can be a therapeutic effective, being capable of reducing and / or controlling the tumor rest, avoiding the need of radiotherapy and / or further surgery. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

BATISTA, RAFAEL LOCH; TRARBACH, ERICKA BARBOSA; MARQUES, MATEUS DINIZ; CESCATO, VALTER ANGELO; DA SILVA, GILBERTO OCHMAN; BORBA HERKENHOFF, CLARISSA G.; CUNHA-NETO, MALEBRANCHE BERARDO; MUSOLINO, NINA ROSA. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile. WORLD NEUROSURGERY, v. 120, p. E241-E246, DEC 2018. (14/16327-1)

BATISTA, RAFAEL L.; MUSOLINO, NINA R. C.; CESCATO, VALTER A. S.; DA SILVA, GILBERTO O.; MEDEIROS, RAPHAEL S. S.; HERKENHOFF, CLARISSA G. B.; TRARBACH, ERICKA B.; CUNHA-NETO, MALEBRANCHE B.. Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, v. 42, n. 2, p. 221-227, FEB 2019. (14/16327-1)